There’s a new Olay skin care product in town.

The brand launched its new Regenerist Niacinamide + Peptide 24 Face Moisturizer, which looks to strengthen skin, even complexions and visibly correct wrinkles.

Featuring a formula that provides 24-hour hydration that looks to hydrate and repair the skin for a stronger barrier, it contains 99% pure niacinamide, peptides and glycerin to penetrate 10 layers deep in the skin’s surface, the company said.  

Olay’s Regenerist Niacinamide + Peptide 24 Face Moisturizer retails for $30.

The Food and Drug Administration has approved Roche’s Lunsumio (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Lunsumio, a CD20xCD3 T-cell engaging bispecific antibody, represents a new class of fixed-duration cancer immunotherapy, which is off-the-shelf and readily available, so that patients do not have to wait to start treatment. Lunsumio will be available in the United States in the coming weeks, the company said.

“This approval is a significant milestone for people with relapsed or refractory follicular lymphoma, who have had limited treatment options until now,” said Elizabeth Budde, Haematologic Oncologist and associate professor at the City of Hope division of Lymphoma, department of Hematology and Hematopoietic Cell Transplantation, and Lunsumio clinical trial investigator. “As a first-in-class T-cell engaging bispecific antibody that can be initiated in an outpatient setting, Lunsumio’s high response rates and fixed-duration could change the way advanced follicular lymphoma is treated.”

“Despite treatment advances, follicular lymphoma remains incurable and relapse is common, with outcomes worsening following each consecutive treatment,” said Levi Garraway, Roche’s chief medical officer and head of global product development. “Lunsumio represents our first approved T-cell engaging bispecific antibody and builds on our legacy of more than 20 years of innovation in blood cancer.”

The Food and Drug Administration approved Gilead Sciences’ Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance or safety considerations.

After the starting dose is completed, Sunlenca is administered as subcutaneous (under the skin) injections once every six months, allowing convenient dosing for patients.

"Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options," said Debra Birnkrant, director of the division of antivirals in the FDA's Center for Drug Evaluation and Research. "The availability of new classes of antiretroviral medications may possibly help these patients live longer, healthier lives."

Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus' protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle. Sunlenca's starting dose is given as oral tablets and subcutaneous injections, followed by maintenance injections every six months; Sunlenca is given in combination with other antiretroviral(s).

Designer Greetings has acquired Oklahoma City master greeting card distributor QPS and their sub distributors: United Wholesale, Cards N Such, Intermountain Greetings, Cards Plus, Northwest Cardco, MDS, Maida and Kibby.

This is the largest acquisition of a greeting card distributor in North America’s history and marks the 17th acquisition for Designer Greetings.

Designer Greetings CEO and president, Steven Gimbelman, said, “QPS has been a distribution partner of Designer Greetings for over 15 years. We’ve developed a solid relationship over the years and the natural progression for an acquisition was imminent. QPS, under the leadership of Paul Casperson, grew the business over the years from repeated greeting card distributor acquisitions, namely United Wholesale, Northwest Cardco, Cards N Such, Intermountain Greetings, Cards Plus, MDS, Maida and Kibby.  QPS has always provided excellent product and superior service to its thousands of partner retailers throughout the United States. We are happy to welcome QPS to our family of partner acquisitions.”

There’s a new way to experience Native’s aluminum and paraben-free stick deodorants.

New from the brand is its line of Deodorant and Body Sprays, which are ozone-friendly and natural propellant spray that offers all-day odor protection.

Featuring water, fragrance and such plant-oil derived skin conditioning ingredients as caprylic/capric triglyceride and dipropylene glycol to help keep users fresh, it also contains denaturated alcohol made from plants for fast-drying, the company said.

Available scents include coconut and vanilla, cucumber and mint, eucalyptus and mint, lilac and white tea, sea salt and cedar, and sweet peach and nectar.

Retailing for $14 each, Native’s new Deodorant and Body Sprays are available for purchase online.

Siggi’s is expanding its iconic Icelandic skyr products with the launch of a new line — rich and creamy skyr.

Featuring an inspired twist of the brand’s iconic product, this latest innovation has whole milk, contains 10 g of protein per serving and comes in zesty lemon, ripe cherry and vanilla honey flavors.

Mostly available on the East Coast, retailers that carry the line include Whole Foods, Hannaford’s, Stop & Shop, Giant, Wegmans, Big Y and Wakefern, the company said. 

Siggi’s rich and creamy skyr retails for $1.89.